Key takeaways:
- Ecnoglutide is a brand new GLP-1 receptor agonist being investigated for weight administration.
- As soon as-weekly remedy additionally improved cardiometabolic danger elements and decreased liver fats content material.
CHICAGO — Adults with chubby or weight problems who acquired once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and sustained reductions in physique weight in contrast with placebo, in keeping with knowledge from the part 3 SLIMMER research.
Ecnoglutide (Sciwind Biosciences) had a good security profile and improved different key cardiometabolic danger elements, whereas additionally decreasing liver fats content material, Linong Ji, MD, endocrinologist and professor at Peking College Individuals’s Hospital, China, informed Healio through e mail.
Ecnoglutide, a novel once-weekly GLP-1, induced weight lack of as much as 13.2% at 40 weeks for adults with chubby or weight problems. Picture: Adobe Inventory
Ecnoglutide is a first-in-class, long-acting, cyclic adenosine monophosphate (cAMP)-biased GLP-1 receptor agonist at present in improvement. Ji informed Healio that “in contrast to unbiased GLP-1 therapies, ecnoglutide selectively prompts cAMP signaling pathways whereas minimizing beta-arrestin recruitment, a mechanism which will clarify its enhanced efficacy of physique weight discount and sustained metabolic results.”
Outcomes of the SLIMMER research have been reported on the American Diabetes Affiliation Scientific Session and likewise printed in The Lancet Diabetes & Endocrinology.
SLIMMER was a randomized, double-blind, placebo-controlled, part 3 trial carried out at 36 websites in China. Researchers enrolled adults with chubby or weight problems (BMI 28 kg/m2 or 24 kg/m2 with a number of weight-related comorbidities). Members didn’t have diabetes. The imply age of contributors was 34 years, half have been ladies and imply BMI at baseline was 32.5 kg/m2.
The researchers randomly assigned 664 contributors to once-weekly subcutaneous ecnoglutide 1.2 mg, 1.8 mg or 2.4 mg or to matching doses of placebo.
At 40 weeks, imply p.c change in physique weight from baseline was –9.1% with ecnoglutide 1.2 mg, –10.9% with ecnoglutide 1.8 mg and –13.2% with ecnoglutide 2.4 mg, in contrast with 0.1% with placebo (P < .0001 for all), in keeping with the outcomes.
The proportion of contributors who achieved a 5% or better discount in physique weight at 40 weeks was 77% within the ecnoglutide 1.2 mg group, 84% within the 1.8 mg group and 87% within the 2.4 mg group in contrast with 16% within the placebo group (P < .0001 for all).
After 48 weeks, sufferers assigned ecnoglutide achieved a 15.4% weight discount, with 92.8% of sufferers attaining clinically significant weight reduction, in keeping with Ji.
“Sufferers within the 1.8 mg and a couple of.4 mg teams continued to have weight reduction at week 48 with out reaching a plateau, indicating that even better weight reduction is perhaps achievable with prolonged ecnoglutide remedy in long-duration research,” Ji informed Healio through e mail.
The researchers additionally reported important enhancements with ecnoglutide vs. placebo in weight-related parameters together with BMI and waist circumference and in cardiometabolic danger elements together with systolic blood strain, lipids, fasting glucose, HbA1c, insulin stage and uric acid. Liver fats content material was decreased with ecnoglutide in a subgroup of contributors with elevated liver fats content material ( 8%) at baseline.
Hostile occasions occurred extra within the ecnoglutide teams (93% vs. 84%). Delicate to reasonable gastrointestinal-related occasions have been commonest. Ten contributors assigned ecnoglutide stopped remedy due to antagonistic occasions, in keeping with the outcomes.
“Contemplating the excessive efficiency of ecnoglutide, it would function a viable possibility for people who don’t obtain ample weight discount with current GLP-1 receptor agonists at their accepted doses or want to realize a bigger discount in physique weight,” Ji informed Healio through e mail.
Reference:
Sources/Disclosures
Collapse
Ji L, et al. 164-OR. Introduced at: American Diabetes Affiliation Scientific Classes; June 20-23, 2025; Chicago.
Disclosures:
The SLIMMER research was funded by Hangzhou Sciwind Biosciences.
